Karyopharm Therapeutics Inc. (KPTI) vs Sangamo Therapeutics, Inc. (SGMOQ)

Karyopharm Therapeutics Inc. and Sangamo Therapeutics, Inc. are both Biotechnology companies. Karyopharm Therapeutics Inc. and Sangamo Therapeutics, Inc. are of similar size ($41.9M and $39.2M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −45.8%. Karyopharm Therapeutics Inc. has the higher net margin (−153.3% vs −356.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Karyopharm Therapeutics Inc. leads on 11 and Sangamo Therapeutics, Inc. on 5.

Valuation

Metric KPTI SGMOQ Biotechnology median
P/E n/m n/m 7.88
P/S 0.32 1.58 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.58 1.79 10.73
Earnings yield (874.99%) (271.43%) (28.84%)
Free cash flow yield (139.70%) (165.83%) (23.03%)

Profitability

Metric KPTI SGMOQ Biotechnology median
Gross margin 95.89% 100.00% 65.16%
Operating margin (56.17%) (357.55%) 0.00%
Net margin (153.28%) (356.89%) 0.00%
Free cash flow margin (44.57%) (261.76%) 0.00%
Return on equity 78.98% 1,755.72% (57.72%)
Return on assets (207.90%) (168.79%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KPTI SGMOQ Biotechnology median
Revenue growth (TTM) 6.81% (45.80%) 5.64%
EPS growth (last fiscal year) (98.37%) 10.20% —
Revenue growth, 5-year CAGR 6.21% (19.66%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KPTI SGMOQ Biotechnology median
Debt to equity (0.76) 0.00 0.00
Current ratio 0.79 0.70 4.73
Net debt to EBITDA (2.03) 0.18 0.96

Dividend

Metric KPTI SGMOQ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric KPTI SGMOQ Biotechnology median
Market cap 39.24m 41.89m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack